Somewhere in the last few days Mississippi became only the second state (after Florida) to average more daily deaths from COVID than all previous waves.
Only 43% are fully vaccinated in Mississippi.
It's pretty hard to exceed peaks set prior to arrival of vaccines. It's a cause for concern. Louisiana and Georgia are nearing this level and I hope rates in those states goes down soon.
Thanks to @CharlesRenPara1 for this figure which plots COVID ICU hospitalization per million versus % fully vaccinated by state/province in USA (blue) and Canada (red). You may have to zoom in to see the details.
Vaccines work really well.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
The FDA seems to have been more lenient on who should get the booster dose than the CDC panel. How's is that going to play out?
Unlike the FDA, the CDC panel has not recommended a booster for those at high risk of occupational exposure. Something that an FDA advisory panel unanimously voted to recommend to the FDA. And the FDA obliged.
So we have an FDA approved EUA indication that is not recommended by the CDC panel.
Unless CDC director revises it, I think it will be interesting how this plays out for healthcare workers and teachers.
CASSIOPEIA trial maintenance results in myeloma: Main takeaway is that daratumumab maintenance provided ZERO benefit if daratumumab was given as induction/consolidation
This PFS curve (blue versus yellow line) should have been in the main paper, not the Appendix. @TheLancetOncol
Key points
1) When this trial was designed we were already using lenalidomide maintenance as standard. This trial had a no treatment control arm. So the question is how good is Dara maintenance against Len. Not Dara maintenance against nothing.
2) If 6 cycles of Dara given upfront provides the same as many years of Dara maintenance, it is preferable to give the Dara at induction. Not as maintenance.
The myeloma field is moving in this direction giving Dara upfront.
Two doses of J&J vaccine provide outstanding protection against COVID. Wish J&J vaccine had always been a two dose approach from the outset , from when they designed the phase III trial. cnn.com/2021/09/21/hea…